SomaLogic, Inc.: management transactions · United States · SEC (Form 4)

About SomaLogic, Inc.

SomaLogic, Inc. is a US-based proteomics company focused on measuring proteins at scale to improve biological understanding, biomarker discovery, and disease research. The company built its reputation around the SOMAmer® chemistry and the SomaScan® platform, which are designed to profile thousands of proteins from very small sample volumes. In practical terms, SomaLogic has positioned itself at the intersection of discovery research, translational science, and laboratory-based proteomics services, with a business model that combines technology access, data services, and laboratory testing capabilities. It also operates a CLIA-certified, CAP-accredited laboratory and supports a global network of SomaLogic Authorized Sites. ([somalogic.com](https://somalogic.com/company-overview/?utm_source=openai)) The company is headquartered in Boulder, Colorado, United States, with its operating address listed at 2945 Wilderness Pl., Boulder, CO 80301. SomaLogic has also built a meaningful intellectual property base, including issued patents and pending applications tied to its SOMAmer reagents and multiplex proteomics platform. That IP position has been central to its differentiation, especially in a competitive proteomics market where assay depth, reproducibility, sensitivity, and sample efficiency are key investor watchpoints. ([somalogic.com](https://somalogic.com/company-overview/?utm_source=openai)) Commercially, SomaLogic serves pharmaceutical and biotechnology companies, academic research institutions, government researchers, and contract research organizations. Its main business lines include fee-for-service proteomics, SomaScan assay services, data consulting services, SomaScan panels, and SomaSignal tests. The value proposition is straightforward: deliver broad protein coverage from minimal sample input, enabling faster work in biomarker discovery, clinical-trial monitoring, and pathway analysis across multiple therapeutic areas. ([somalogic.com](https://somalogic.com/?utm_source=openai)) From a competitive standpoint, SomaLogic operates in a specialized but strategically important slice of precision medicine and multiomics. The company emphasizes large-scale protein coverage, analytical precision, and reproducibility, and it points to an extensive publication record and large proteomic datasets as evidence of technical traction. Geographically, its operational base is in the United States, while its commercial reach is global through authorized sites and service partnerships. ([somalogic.com](https://somalogic.com/?utm_source=openai)) The most important recent development is strategic rather than purely operational: Illumina announced and then completed its acquisition of SomaLogic, with closing on January 30, 2026. That transaction integrates SomaLogic’s proteomics platform into a larger multiomics ecosystem and should be viewed as the defining near-term event for investors following SLGCW on the US-listed NYSE/NASDAQ complex. It may improve distribution and strategic relevance, but it also means the equity story must now be interpreted through the lens of ownership change and post-acquisition integration. ([illumina.com](https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=b7bf54f5-b534-47b4-a629-02ade3b10178&utm_source=openai))